{
    "clinical_study": {
        "@rank": "56857", 
        "arm_group": [
            {
                "arm_group_label": "Schedule A", 
                "arm_group_type": "Experimental", 
                "description": "Influenza vaccination on the first day of chemotherapy"
            }, 
            {
                "arm_group_label": "Schedule B", 
                "arm_group_type": "Experimental", 
                "description": "Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial studies the best time to administer the influenza vaccine to patients\n      with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different\n      times relative to chemotherapy may affect how well it works to help the body build an immune\n      response and prevent influenza in these patients."
        }, 
        "brief_title": "Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Influenza, Human"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have biopsy-confirmed non-hematological malignancy\n\n          -  Patients must be scheduled to receive cytotoxic chemotherapy (adjuvant or metastatic\n             setting), excluding immunotherapy\n\n          -  Patients must be of age >=18 years.\n\n          -  Patients must have an absolute lymphocyte count >= 1,000/mcL immediately prior to\n             influenza vaccination\n\n          -  Ability of the patient (or legally authorized representative if applicable) to\n             understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have already received the influenza vaccine during the season in which\n             they are considered for eligibility will be excluded\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to the influenza vaccine or egg allergies\n\n          -  Previous history of Guillian-Barre syndrome within the previous 6 weeks to influenza\n             vaccination\n\n          -  Patients must not be receiving chronic steroid therapy, defined as >= 14 days, unless\n             used as part of a chemotherapy regimen\n\n          -  Patients must not be on any other agents that can suppress the immune system\n\n          -  Planned concurrent therapy with radiation\n\n          -  Uncontrolled illness at time of enrollment or influenza vaccination including, but\n             not limited to, ongoing or active febrile illness\n\n          -  Psychiatric illness/social situations that would limit compliance with study\n             requirements\n\n          -  Known immunosuppression eg. history of organ transplantation or known human\n             immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy\n             are ineligible because they may not be able to mount an appropriate immune response\n\n          -  History of influenza-like illness, defined as a temperature > 37.8 degree C with\n             cough or sore throat starting October 1, 2011 throughout the duration of the study\n\n          -  Patient may not be scheduled to receive chemotherapy on a weekly basis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695733", 
            "org_study_id": "201010722"
        }, 
        "intervention": {
            "arm_group_label": [
                "Schedule A", 
                "Schedule B"
            ], 
            "intervention_name": "trivalent influenza vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Flushield, Fluvirin, Fluzone, Influenza Vaccine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 4, 2013", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Influenza Vaccination Response in Patients With Non-Hematological Malignancies", 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Saiama Waqar, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "We will assess co-primary endpoints of serologic response to the H3N2 and H1N1 strains in the 2011-2012 and 2012-2013 seasonal influenza vaccine.", 
            "measure": "Optimal timing of seasonal influenza vaccination with regard to chemotherapy administration schedule.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks from the influenza vaccine"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695733"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Report the presence of post-vaccination adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks from the influenza vaccine"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013", 
        "why_stopped": "no longer had funding to continue"
    }
}